Company Filing History:
Years Active: 2009-2016
Title: The Innovations of Richard Mallonee
Introduction
Richard Mallonee is an accomplished inventor based in Baltimore, MD, with a notable portfolio of four patents. His work primarily focuses on advancements in nucleic acid detection methods, which have significant implications in clinical diagnostics.
Latest Patents
Among his latest patents is the "Fast results hybrid capture assay and associated strategically truncated probes." This invention discloses strategically truncated probes that are specific for high-risk HPV nucleic acids, allowing for fast and reliable detection of human papillomavirus in clinical samples without significant cross-reaction. Another significant patent is the "Detection of nucleic acids by target-specific hybrid capture method." This method, known as target-specific hybrid capture (TSHC), provides a rapid, sensitive, and highly specific nucleic acid detection technique capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids that can be detected by various methods.
Career Highlights
Richard Mallonee is currently employed at Qiagen Gaithersburg Inc., where he continues to contribute to the field of molecular diagnostics. His innovative approaches have enhanced the accuracy and efficiency of nucleic acid detection, making a substantial impact on clinical practices.
Collaborations
Throughout his career, Mallonee has collaborated with notable colleagues, including Irina A Nazarenko and Attila T Lorincz. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Richard Mallonee's contributions to the field of nucleic acid detection exemplify the importance of innovation in medical diagnostics. His patents reflect a commitment to improving clinical outcomes through advanced technology.